Reverse-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Peptide reconstitution is the process of dissolving a lyophilized peptide powder in a liquid solvent to produce a solution of defined concentration. Lyophilization removes water under vacuum from a frozen peptide solution, leaving a porous cake or powder. The dry form is often more stable for shipping and storage. Reconstitution restores the peptide to a liquid state for analytical, biochemical, or formulation work. The exact solvent depends on peptide sequence and intended assay.
Water is common, but not universal; hydrophobic peptides may require organic co-solvents like acetonitrile or dimethyl sulfoxide. Acidic peptides may dissolve better in dilute acetic acid or ammonium hydroxide, while basic peptides may favor slightly acidic conditions. Buffer choice matters because pH can affect charge, solubility, and aggregation. Some peptides require sonication or gentle mixing, whereas vigorous vortexing can cause foaming and surface denaturation. The target concentration is typically calculated from the labeled peptide mass and the volume of solvent added.
Dissolution involves hydration of polar and charged groups, disruption of intermolecular interactions in the lyophilized powder, and transition to a thermodynamically favored solution state. Not all powder dissolves readily; aggregation, incomplete lyophilization, or high molecular weight can slow reconstitution. The resulting solution may contain particulates or oligomers that affect downstream measurements. Researchers often verify complete dissolution by visual inspection and spectrophotometric or chromatographic methods. The relationship between reconstitution conditions and long-term stability remains an active area of study.
Storage conditions for reconstituted peptides are product-specific. Cool temperatures slow many degradation pathways, but freezing can concentrate solutes and promote aggregation. Light exposure can oxidize susceptible residues such as methionine, cysteine, or tryptophan. Oxygen in headspace can contribute to oxidation, while acidic or basic pH can drive hydrolysis and deamidation. The best storage condition for a given sequence is often determined empirically because general rules do not capture all sequence-specific effects.
Quality control of reconstituted peptides combines visual inspection with instrumental analysis. A clear solution does not prove correct identity or purity, and a cloudy solution does not always indicate failure. Reverse-phase high-performance liquid chromatography can separate the peptide from related impurities, while mass spectrometry confirms molecular mass and detects modifications. pH measurement and osmolality checks provide additional information about the solution environment, and documentation of lot number, solvent, and storage history supports traceability.
After a peptide is reconstituted, handling practices affect its chemical and physical stability over time. Aqueous solutions can support microbial growth unless they are prepared with aseptic technique or contain preservatives. Container material matters because peptides can adsorb to glass or plastic surfaces, reducing the amount available in solution. Repeated transfers increase exposure to air and potential contaminants, and temperature fluctuations can accelerate degradation. These factors are separate from the peptide's intrinsic sequence-based stability.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder or cake | Appearance varies from white to off-white with peptide sequence and fill. |
| Solubility class | Variable; often water-soluble | Hydrophobic sequences may require an organic co-solvent. |
| Common solvent | Sterile water or aqueous buffer | Choice depends on peptide charge and assay compatibility. |
| Typical pH range | 2 to 8 | Outside this range may accelerate degradation for some peptides. |
| Common analytical check | RP-HPLC | Confirms identity and purity after dissolution. |
Quality records typically include a certificate of analysis, batch number, molecular weight, purity result, and recommended storage conditions. After reconstitution, a laboratory log may record solvent, final volume, date, and storage location. Such documentation supports reproducibility and allows later investigation if a preparation behaves unexpectedly. Stability studies often examine purity and concentration over time under defined temperatures, but results are not universally transferable between peptides or formulations. Open questions remain about how best to predict aggregation for specific sequences and how much analytical testing is sufficient for routine laboratory work.
After a peptide is reconstituted, analytical checks can confirm identity, concentration, and purity. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry provides a mass value that supports sequence identity, while ultraviolet absorbance at 214 or 280 nanometers is often used for concentration estimation when the extinction coefficient is known. These methods answer different questions and are complementary. A single measurement rarely establishes full quality, because the same sample can appear acceptable by one method and fail another.
Concentration calculations depend on the amount of peptide present in the vial and the volume of solvent added. Lyophilized preparations often contain counterions, salts, or residual water, so the labeled mass may not equal the mass of the peptide itself. This difference can produce a calculated concentration that is higher than the true peptide concentration. Analytical determination of peptide content, rather than reliance on the vial label alone, reduces this source of error. Uncertainty in volume measurement also contributes, especially when small liquid volumes are handled.
Aseptic technique matters because aqueous peptide solutions can support microbial growth. Sterile solvents, clean workspaces, and sterile filtration can reduce contamination. The choice of filter material and pore size must avoid peptide loss through adsorption, especially for hydrophobic or low-concentration samples. Visual inspection for particles, turbidity, or color change provides a simple initial check, but it cannot confirm identity or purity. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to verify composition and detect degradation products.
Documentation supports reproducibility and traceability. Records often include lot number, solvent composition, final concentration, preparation date, and storage location. Such details help distinguish procedural variation from actual sample instability. Questions remain about how best to predict long-term stability from short-term accelerated studies, because peptide degradation pathways differ widely. For many peptides, the relationship between in vitro solution stability and biological behavior is incompletely understood and is an active area of research.
Post-transcriptional expression levels of many genes can be controlled by RNA interference, in which miRNAs, specific short RNA molecules, pair with mRNA regions and target them for repression. RNA interference is carried out by the RNA-induced silencing complex, which uses a miRNA guide to regulate complementary mRNAs through base pairing interactions and results in either degradaing the mRNA or blocking its translation.
== Pharmacokinetics and pharmacogenetics == It is bioactivated hepatically to its primary metabolite, N-desethylamodiaquine, by the cytochrome p450 enzyme CYP2C8. Among amodiaquine users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles. CYP2C8*1 is characterized as the wild-type allele, which shows an acceptable safety profile, while CYP2C8*2, *3 and *4 all show a range of "poor metabolizer" phenotypes. People who are poor metabolizers of amodiaquine display lower treatment efficacy against malaria, as well as increased toxicity. Several studies have been conducted to determine the prevalence of CYP2C8 alleles amongst malaria patients in East Africa, and have tentatively shown the variant alleles have significant prevalence in that population. About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with amodiaquine. This information is useful in developing programs of pharmacovigilance in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.
The green fluorescent protein (GFP) is a protein that exhibits green fluorescence when exposed to light in the blue to ultraviolet range. The label GFP traditionally refers to the protein first isolated from the jellyfish Aequorea victoria and is sometimes called avGFP. However, GFPs have been found in other organisms including corals, sea anemones, zoanithids, copepods and lancelets. The GFP from A. victoria has a major excitation peak at a wavelength of 395 nm and a minor one at 475 nm. Its emission peak is at 509 nm, which is in the lower green portion of the visible spectrum. The fluorescence quantum yield (QY) of GFP is 0.79. The GFP from the sea pansy (Renilla reniformis) has a single major excitation peak at 498 nm. GFP makes for an excellent tool in many forms of biology due to its ability to form an internal chromophore without requiring any accessory cofactors, gene products, or enzymes / substrates other than molecular oxygen. In cell and molecular biology, the GFP gene is frequently used as a reporter of expression. It has been used in modified forms to make biosensors, and many animals have been created that express GFP, which demonstrates a proof of concept that a gene can be expressed throughout a given organism, in selected organs, or in cells of interest. GFP can be introduced into animals or other species through transgenic techniques, and maintained in their genome and that of their offspring. GFP has been expressed in many species, including bacteria, yeasts, fungi, fish and mammals, including in human cells. Scientists Roger Y.
According to the Romania's National Institute of Statistics (INS), Romania's total road network was estimated in 2015 at 86,080 kilometres (53,488 mi). The World Bank estimates the railway network at 22,298 kilometres (13,855 mi) of track, the fourth-largest railway network in Europe. Romania's rail transport experienced a dramatic decline after 1989 and was estimated at 99 million passenger journeys in 2004, but has experienced a recent (2013) revival due to infrastructure improvements and partial privatisation of lines, accounting for 45% of all passenger and freight movements in the country. Bucharest Metro, the only underground railway system, was opened in 1979 and measures 80.01 km (49.72 mi) with an average ridership in 2021 of 720,000 passengers during the workweek in the country. There are sixteen international commercial airports in service today. Over 12.8 million passengers flew through Bucharest's Henri Coandă International Airport in 2017. Romania is a net exporter of electrical energy and is 52nd worldwide in terms of consumption of electric energy. Around a third of the produced energy comes from renewable sources, mostly as hydroelectric power. It has one of the largest refining capacities in Eastern Europe, even though oil and natural gas production has been decreasing for more than a decade. With one of the largest reserves of crude oil and shale gas in Europe it is among the most energy-independent countries in the EU, and is looking to expand its nuclear power plant at Cernavodă further.
Sources: en.wikipedia.org
== Benign neoplasms (210–229) == 210 Benign neoplasm of lip, oral cavity, and pharynx 211 Benign neoplasm of other parts of digestive system 211.3 Colon Familial adenomatous polyposis 212 Benign neoplasm of respiratory and intrathoracic organs 212.0 Nasal cavities middle ear and accessory sinuses 212.1 Larynx 212.2 Trachea 212.3 Bronchus and lung 212.4 Pleura 212.5 Mediastinum 212.6 Thymus 212.7 Heart Myxoma Rhabdomyoma 213 Benign neoplasm of bone and articular cartilage 213.9 Bone and articular cartilage, site unspecified Chondroma 214 Lipoma 215 Other benign neoplasm of connective and other soft tissue 216 Benign neoplasm of skin Melanocytic nevus 217 Benign neoplasm of breast 218 Uterine leiomyoma 219 Other benign neoplasm of uterus 220 Benign neoplasm of ovary 221 Benign neoplasm of other female genital organs 222 Benign neoplasm of male genital organs 223 Benign neoplasm of kidney and other urinary organs 224 Benign neoplasm of eye 225 Benign neoplasm of brain and other parts of nervous system 226 Benign neoplasm of thyroid glands 227 Benign neoplasm of other endocrine glands and related structures 228 Hemangioma and lymphangioma, any site 228.0 Hemangioma, any site 228.1 Lymphangioma, any site 229 Benign neoplasm of other and unspecified sites
== Epidemiology == Accurate epidemiological data on the prevalence of cachexia is lacking due to changing diagnostic criteria and under-identification of people with the disorder. It is estimated that cachexia from any disease is estimated to affect more than 5 million people in the United States. The prevalence of cachexia is growing and estimated at 1% of the population. The prevalence is lower in Asia but due to the larger population, represents a similar burden. Cachexia is also a significant problem in South America and Africa. In people with cancer, prevalence of cachexia was previously reported to range from 11% to 71%. Recent updates show that 33%-51.8% of people with cancer develop cachexia, though estimates vary widely and may be unreliable due to absence of consensus guidelines for diagnosis, variability in cancer populations, and variability in timing of diagnosis. Specifically, the highest rates were seen in older populations as well as those with upper gastrointestinal, colorectal, and lung cancers, respectively. The prevalence increases in advanced cancer stages, affecting up to 80% of terminal cancer cases. The most frequent diseases causing cachexia in the United States are: 1) cancer, 2) chronic heart failure, 3) chronic kidney disease, 4) COPD. Cachexia contributes to significant loss of function and healthcare utilization. Estimates suggest that cachexia accounted for 177,640 hospital stays in 2016 in the United States. Cachexia is considered the immediate cause of death of many people with cancer, estimated between 22 and 40%.
On March 15, OSFI took permanent control of the bank and announced it would restructure SVB Canada to a new bridge bank to be created by the FDIC, after the regulator was unable to find a buyer. An initial auction of Silicon Valley Bank assets on March 12 attracted a single bid that was not from a bank, after PNC Financial Services and RBC Bank backed away from making offers. Bank of America, JPMorgan Chase, and Goldman Sachs all declined to make offers. The FDIC canceled the auction, scheduling a second to attract bids from major banks, after the systemic risk exception was granted. Mayopoulos urged venture capitalists and startups to keep their deposits in the bridge bank, apparently to improve its financial condition, and suggested that customers return some of the deposits they had recently pulled out of the bank as part of a diversification strategy. A group of venture capitalists called for depositors to keep at least half of their capital in the bank. The seizure of Silicon Valley Bank's assets severely disrupted SVB Financial Group's operations. The holding company was locked out of its Santa Clara headquarters, which were shared with the bank, forcing it to move its headquarters to its New York City offices. The holding company, bridge bank, and FDIC are discussing how to reorganize payroll systems. All of SVB Financial Group's employees have been on the payroll of Silicon Valley Bank, not SVB Financial Group, while the parent company has been providing employee benefits to all Silicon Valley Bank employees.
The three substrates of this enzyme are N-succinyl-L-glutamic 5-semialdehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are N-succinyl-L-glutamic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is N-succinyl-L-glutamate 5-semialdehyde:NAD+ oxidoreductase. Other names in common use include succinylglutamic semialdehyde dehydrogenase, N-succinylglutamate 5-semialdehyde dehydrogenase, SGSD, AruD, and AstD. This enzyme participates in arginine and proline metabolism.
Colin Ayton Greenhalgh, Principal, Hills Road Sixth Form College, Cambridge. For services to Education. Ian Gregg, Chairman, River Tweed Commissioners and Tweed Foundation. For services to Salmon and Trout Fishing. Vernon Charles Grove, Administrator, Wales and Chester Circuit, Lord Chancellor's Department. Rex Farrow Gyngell, . For political and public service. Arthur Barry Haines, Chair, Aerodynamics Group, Royal Aeronautical Society. For services to Aerodynamics. Eunice Hanna. For political service. Lieutenant Colonel Grattan Herbert Hart, . For services to the Royal British Legion in Sussex. Robert James Hasson, Assistant Controller (Collection and Personnel), Board of Inland Revenue. Anthony Roger Heath. For services to the Administration of Justice. Jennifer Mary Toresen, Lady Hemingford. For services to the community in Hemingford Abbots, Cambridgeshire and to the British Red Cross Society. Desmond Charles Henley, Embalmer. For services in the Aftermath of Disasters. Damon Graham Hill. For services to Motor Racing. John William Hoaen, Grade 7, Department of Trade and Industry. Margaret Edith Hobrough, Principal and Chief Executive, Godalming Sixth Form College, Surrey. For services to Education. Brigadier David Hendry Hodge, . For services to the Territorial Auxiliary and Volunteer Reserve Association in the North of England. The Reverend Roger Graham Holloway. For services to Export. John Hood. For services to Industry. John Trevor Hopkins, Headmaster, Bishop Stopford School, Kettering, Northamptonshire. For services to Education.
Sources: en.wikipedia.org
Stained brain slice images which include the "Hypothalamus" at the BrainMaps project The Hypothalamus and Pituitary at endotexts.org NIF Search - Hypothalamus via the Neuroscience Information Framework Space-filling and cross-sectional diagrams of hypothalamic nuclei: right hypothalamus, anterior, tubular, posterior.
=== Internment camps and Polish refugees === Thousands of Axis POWs and people described as "enemy aliens" were held in Southern Rhodesia during the conflict. These were mainly Italians and Germans, but there were also a handful from Iraq and the Levant; the colony furthermore hosted nearly 7,000 refugees from Poland. Britain delegated responsibility for co-ordinating investigation into enemy aliens in central Africa to the Southern Rhodesian government, which set up a system whereby the Criminal Investigation Department (CID) identified potential detainees while a body called the Internment Camps Corps oversaw the camps. Many of those held in Southern Rhodesia were sent there by Britain or authorities elsewhere in the Empire. Five internment camps were set up in two waves. No. 1 (General) Internment Camp opened to the north-east of Salisbury in October 1939 and No. 2 (Tanganyika) Internment Camp, just south of the city, opened the following year, mostly housing Germans formerly resident in Tanganyika. The first two camps together had less than 800 inmates. The third, fourth and fifth camps were set up near Gatooma, Umvuma and Fort Victoria in 1941–42 to accommodate roughly 5,000 Italians from Somaliland and Abyssinia. The Internment Camps Corps' reliance on the elderly, the infirm and so-called "friendly aliens" to staff the three new camps led to indiscipline, poor living conditions and dozens of escapes. A 1943 government commission into the quality of the internment camps reported the second wave camps to be of far worse quality than those of the first wave.
There's no way it (KFC) could have grown as it did without the Collectramatic. Stores were doing about $200,000 a year in sales on average with the pots...but they could never have done the $900,000 a year it became without Win's fryer. He (Shelton) helped set the stage for that with true engineering thinking. Although a number of franchisees bought the Collectramatic, which had the support of Colonel Sanders from 1970 onwards, John Y. Brown Jr. had given tacit approval to franchisees to exclusively use the older L S Hartzog fryer, saying "Though those old pots were damn dangerous, at least we knew they worked! I was mostly afraid these new fryers would break down in the middle of business." Brown warned franchisees that they were in violation of their contract if they used the Collectramatic. Brown held his ground on the issue until he learned that his father, John Y. Brown Sr., who owned multiple KFC franchises, was successfully using the Collectramatic in every franchise he owned. The issue was eventually resolved after Heublein purchased KFC, acquired Hartzog and nullified the contract. The Collectramatic has been an approved pressure fryer for KFC from 1972 onwards. From 2013 onwards, KFC has been transitioning from using Collectramatic cookers to pressure fryers produced by Henny Penny, which supplies KFC with various equipment. The 'Velocity' series of pressure fryers includes increased load capacity, automatic oil filtration and increased oil longevity.
=== London Hospital === Florey was unhappy working at London Hospital; he disliked the long daily commute from Chobham that put his experimental work at the mercy of the railway timetable. In the summer Howard and Ethel lived in a flat in Belsize Park so he could devote more time to his work. He wrote up the results of the research he had done in New York on lacteals and lymphatic capillaries, which was published in the Journal of Physiology in 1927. Florey then embarked on writing a thesis for a fellowship at Gonville and Caius College, Cambridge, where he became an unofficial fellow in 1926. His thesis on "Physiology and pathology of the circulation of the blood and lymph" was accepted, and his fellowship awarded in 1927. He also continued his work on the secretion of mucus. London Hospital's facilities for the laboratory animals he needed for his research were unsatisfactory, so these experiments were carried out at Oxford and Cambridge. However, he was able to study the lacteals in patients undergoing abdominal surgery.
Sources: en.wikipedia.org
Lyophilized peptide is a dry powder made by freeze-drying, while reconstituted peptide is dissolved in a solvent. The dry form generally offers longer storage at appropriate temperatures. Reconstitution introduces water and increases the risk of degradation.
No single solvent works for all peptides. The choice depends on sequence, charge, hydrophobicity, and assay compatibility. Water, aqueous buffers, and organic co-solvents are common, but each can alter peptide behavior.
Not always. Some peptides are supplied as pre-dissolved solutions or in formulations ready for a specific assay. Reconstitution is mainly needed when the supplied form is a lyophilized powder, and the required format depends on the intended application.
There is no universal storage time because stability depends on sequence, solvent, pH, concentration, and temperature. Product-specific data or stability studies provide the most reliable guidance. In the absence of such data, short-term cold storage is common.